Discontinuing Antidepressants in MDD: Timing, Tapering, and Relapse
Managing Unipolar Depression: The Delicate Process of Stopping Treatment
In a discussion dedicated to managing unipolar affective disorder, experts analyze the delicate process of stopping antidepressant treatment. This clinical decision is as critical as the initial prescription, and in practice it is often executed incorrectly. Dr. Alva emphasizes that the timing and method of medication withdrawal often matter more than the initial treatment choice.
Wellness insights:
Dr. Clayton directly addresses the problem of overlapping prescriptions, pointing out that administering two SSRI medications, or a combination of SSRI with an SNRI, lacks mechanistic logic because the receptors are already saturated. This dual therapy should be eliminated. The same rule applies when two treatments work against each other or involve an unacknowledged interaction.
When it comes to the method of stopping, Dr. Clayton makes a distinction based on the duration of medication exposure. If a patient has been treated for only a short period, the withdrawal process can be faster, and discontinuation symptoms are generally minor. She adds a practical note about the agents most associated with withdrawal symptoms. Because she works with women who may become pregnant, she avoids these medications from the start, which reduces risks.
The MDD Pipeline: New Mechanisms Beyond the Monoamine Model
She offers another lever she finds useful: querying the family history. If another family member suffered from depression, what treatment worked for them? This history has real value. If the current medication is not yielding results, the family response can indicate the next choice.
Her summarized position is that clinicians should stop treatment when it no longer works, and they can do this earlier than they usually do. A slow taper is reasonable, especially when a patient has been on medication for six months or more.
Next, in the section „The MDD Pipeline: New Mechanisms Beyond the Monoamine Model,” Dr. DeBattista tempers the enthusiasm around a pipeline that is finally moving beyond the monoamine model.
More stories: